SOHO 2026 | Managing patients with CML and additional genetic abnormalities
Jorge Cortes
• 10 Sep 2026
Jorge Cortes, MD, The University of Alabama at Birmingham, Birmingham, AL, discusses a key unresolved question in chronic myeloid leukemia (CML): how to manage patients with additional genetic abnormalities at diagnosis, particularly ASXL1 mutations. He emphasizes the need to better understand optimal treatment strategies and the appropriate timing of transplant to improve outcomes in this patient subset. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
